Collaboration and License Agreements - Amgen, Inc. (Details) |
Jun. 30, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Jun. 30, 2025
USD ($)
|
Sep. 30, 2016
agreement
|
|---|---|---|---|---|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Contract assets | $ 10,231,000 | $ 0 | ||
| Contract liabilities included in deferred revenue, current | 94,596,000 | $ 2,399,000 | $ 22,979,000 | |
| Amgen Incorporated | Olpasiran Agreement | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Number of agreements | agreement | 2 | |||
| Contract assets | 0 | |||
| Contract liabilities included in deferred revenue, current | 0 | |||
| Amgen Incorporated | Olpasiran Agreement | Maximum | ||||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||
| Additional remaining development regulatory and sales milestones payments | $ 485,000,000.0 |